These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25388642)

  • 21. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.
    Altomare DA; Wang HQ; Skele KL; De Rienzo A; Klein-Szanto AJ; Godwin AK; Testa JR
    Oncogene; 2004 Jul; 23(34):5853-7. PubMed ID: 15208673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
    Hehlgans S; Eke I; Cordes N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
    Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
    Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
    Fiedler M; Weber F; Hautmann MG; Haubner F; Reichert TE; Klingelhöffer C; Schreml S; Meier JK; Hartmann A; Ettl T
    Clin Oral Investig; 2018 Jan; 22(1):189-200. PubMed ID: 28315964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.
    Brognard J; Clark AS; Ni Y; Dennis PA
    Cancer Res; 2001 May; 61(10):3986-97. PubMed ID: 11358816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival.
    Hartmann W; Küchler J; Koch A; Friedrichs N; Waha A; Endl E; Czerwitzki J; Metzger D; Steiner S; Wurst P; Leuschner I; von Schweinitz D; Buettner R; Pietsch T
    Clin Cancer Res; 2009 Jul; 15(14):4538-45. PubMed ID: 19584164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma.
    Khor TO; Gul YA; Ithnin H; Seow HF
    Cancer Lett; 2004 Jul; 210(2):139-50. PubMed ID: 15183529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teasing out the best molecular marker in the AKT/mTOR pathway in head and neck squamous cell cancer patients.
    Clark C; Shah S; Herman-Ferdinandez L; Ekshyyan O; Abreo F; Rong X; McLarty J; Lurie A; Milligan EJ; Nathan CO
    Laryngoscope; 2010 Jun; 120(6):1159-65. PubMed ID: 20513033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells.
    Liu JJ; Duan RD
    Anticancer Res; 2009 Aug; 29(8):2987-91. PubMed ID: 19661305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V; Bier C; Habtemichael N; Schuon R; Schweitzer A; Kunkel M; Engels K; Kovács AF; Schneider S; Mann W; Stauber RH; Knauer SK
    Int J Cancer; 2009 May; 124(9):2033-41. PubMed ID: 19130609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
    You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
    BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
    Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
    Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.
    Perri F; Pacelli R; Della Vittoria Scarpati G; Cella L; Giuliano M; Caponigro F; Pepe S
    Head Neck; 2015 May; 37(5):763-70. PubMed ID: 24995469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
    Wang H; Liu XB; Chen JH; Wang QQ; Chen JP; Xu JF; Sheng CY; Ni QC
    Exp Mol Pathol; 2014 Oct; 97(2):191-201. PubMed ID: 25036402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
    Amornphimoltham P; Sriuranpong V; Patel V; Benavides F; Conti CJ; Sauk J; Sausville EA; Molinolo AA; Gutkind JS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4029-37. PubMed ID: 15217935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation.
    Yang MH; Chiang WC; Chou TY; Chang SY; Chen PM; Teng SC; Wu KJ
    Clin Cancer Res; 2006 Jan; 12(2):507-15. PubMed ID: 16428493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study.
    Raybaud-Diogène H; Fortin A; Morency R; Roy J; Monteil RA; Têtu B
    J Clin Oncol; 1997 Mar; 15(3):1030-8. PubMed ID: 9060543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.